Lifeward Appoints Bob Marshall as Chairman of the Board
Rhea-AI Summary
Lifeward (Nasdaq: LFWD) announced that its Board appointed Bob Marshall as Chairman, effective January 1, 2026. He will replace Joseph Turk, who will transition off the Board in connection with his new role at Fresenius Medical Care as Chief Executive Officer of Care Enablement.
Marshall has served on Lifeward's Board and as Chair of the Audit Committee since 2024, and is currently CFO and Treasurer of Lantheus Holdings (roles held since 2018). Management says Marshall’s financial leadership and public-company healthcare experience will support Lifeward’s strategic growth plans and patient-care objectives.
Positive
- New chairman effective Jan 1, 2026
- Marshall served as Audit Committee chair since 2024
- Marshall is CFO/Treasurer of Lantheus since 2018
- Board retains public-company healthcare financial expertise
Negative
- Joseph Turk will transition off the Board as of Jan 1, 2026
- Board turnover may reduce continuity from prior chairman
News Market Reaction 6 Alerts
On the day this news was published, LFWD declined 4.41%, reflecting a moderate negative market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $551K from the company's valuation, bringing the market cap to $12M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LFWD gained 6.23% while peers were mixed: RSLS up 29.8%, PAVM down 8.41%, BMRA down 2.14%, and DHAI flat. This points to a more company-specific reaction to the leadership news rather than a uniform medical devices sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Distribution expansion | Positive | +0.1% | Expanded ReWalk exoskeleton distribution into three new international markets. |
| Dec 03 | Reimbursement coverage | Positive | +25.4% | Humana Medicare Advantage approval broadening coverage for ReWalk 7 device. |
| Nov 17 | Reimbursement update | Positive | -0.5% | UnitedHealthcare prior authorization for ReWalk 7 following CMS reimbursement pathway. |
| Nov 14 | Earnings results | Positive | +14.9% | Q3 2025 results with revenue growth, lower cash burn, and reaffirmed guidance. |
| Nov 10 | Earnings date notice | Neutral | +4.1% | Announcement of timing and access details for Q3 2025 earnings call. |
Recent earnings and reimbursement catalysts often coincided with positive price reactions, while one Medicare Advantage prior-authorization update saw a modest pullback, indicating generally constructive but not uniform responses to news.
Over the last two months, Lifeward reported multiple operational and reimbursement milestones plus Q3 2025 financials. On Nov 14, Q3 results with modest revenue growth, reduced cash burn, and a $3.0M loan were followed by a double‑digit gain. Medicare Advantage prior authorizations and broader coverage for the ReWalk 7 device on Nov 17 and Dec 3 produced mixed but overall positive reactions. The Dec 17 international distribution expansion move was nearly flat. Today’s chairman appointment fits into an ongoing period of strategic execution and governance activity.
Market Pulse Summary
This announcement details a planned transition in board leadership, with Bob Marshall becoming chairman effective January 1, 2026. His background as CFO of a public radiopharmaceutical company and prior experience at Zimmer Biomet adds financial and healthcare expertise to Lifeward’s governance. In the past months, Lifeward has reported reimbursement wins, international expansion, and Q3 2025 results, so investors may weigh this leadership change alongside recent financing activity, capital structure proposals, and execution of growth plans.
Key Terms
audit committee financial
AI-generated analysis. Not financial advice.
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care.
“On behalf of the Board and entire Lifeward team, I congratulate Joe on his appointment as Chief Executive Officer of Care Enablement at Fresenius Medical Care, a global leader in renal care,” said Lifeward’s CEO, Mark Grant. “We are grateful for Joe’s leadership and dedicated service to Lifeward, including his stewardship as Chairman, and we wish him tremendous success in his new role.”
Mr. Grant continued, “I’m also pleased to welcome Bob Marshall as our new Chairman. Bob has been a valuable member of our Board and Chair of our Audit Committee since joining in 2024. His financial leadership, healthcare public company expertise, and strategic perspective will be instrumental as we continue to execute on our strategic growth plans and deliver improved care and outcomes for patients.”
Mr. Marshall is Chief Financial Officer and Treasurer of Lantheus Holdings, a publicly traded radiopharmaceutical company, and has served in these roles since 2018. Previously, he spent 16 years at Zimmer Biomet Holdings, in positions including Vice President, Investor Relations and Corporate Treasurer, and most recently Vice President, Americas Finance for the U.S., Canadian, and Latin American commercial markets. Earlier in his career, he held roles of increasing responsibility at Brown & Williamson Tobacco, a subsidiary of British American Tobacco.
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings, as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products, including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany.
Lifeward®, ReWalk®, ReStore®, and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Contact:
Almog Adar
Chief Financial Officer
E: media@golifeward.com
FAQ
When does Bob Marshall become Chairman of Lifeward (LFWD)?
Why is Joseph Turk leaving the Lifeward board (LFWD)?
What relevant experience does new Chairman Bob Marshall bring to Lifeward (LFWD)?
Will Bob Marshall’s appointment change Lifeward’s strategy or reporting timeline (LFWD)?
How does the Lifeward board change affect shareholders of LFWD?
